Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Besivance (Royalty Interest)

M&A STATUS
Buyout/LBO LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Royalty on future sales of an ophthalmic suspension drug. The royalty is for Beivance, (besifloxacin ophthalmic suspension), a treatment for bacterial conjunctivitis.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Primary Office
  • 965 Atlantic Avenue
  • Alameda, CA 94501
  • United States

Besivance (Royalty Interest) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Besivance (Royalty Interest)‘s full profile, request access.

Request full access to PitchBook

Besivance (Royalty Interest) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Besivance (Royalty Interest)‘s full profile, request access.

Request full access to PitchBook